Revvity AlphaLISA SureFire Ultra Human Phospho-Lamin A/C (Ser22) Detection Kit, 500 Assay Points

Lamins are structural components of the nuclear lamina, a protein network underlying the inner nuclear membrane that determines nuclear shape and size. They can be classified as A type and B type. The B-type lamins are expressed in most cell types, whereas A-type lamins, which include lamin C, are generally expressed in differentiated tissues. Lamins are multi-functional proteins, which play important roles in nuclear structure, chromatin organization, gene positioning, DNA replication and repair, as well as cell proliferation, differentiation, and stress responses. Muscular dystrophies, neuropathies, cardiomyopathies, and syndromes of premature aging can all be caused by mutations in the LMNA gene, which codes for lamins A and C. These disorders are collectively referred to as laminopathies.

The AlphaLISA SureFire Human Phospho-Lamin A/C (Ser22) Detection Kit is a sandwich immunoassay for the quantitative detection of phospho-Lamin A/C (Ser22) in cellular lysates, using Alpha Technology.

Formats:

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

Alpha SureFire kits can be used for:

• Cellular kinase assays
• Receptor activation studies
• Screening

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).